Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
(4) - EconoTimes)
EMERYVILLE, Calif., May 01, 2018 -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to six new non-executive employees.
The awards were made on May 1, 2018, under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company. The inducement awards consist of options to purchase an aggregate of 31,500 shares of Zogenix common stock. The options have a ten-year term and an exercise price equal to $40.15, the fair market value of Zogenix common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).
About Zogenix
Zogenix (Nasdaq:ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options but face a critical need. For more information, visit www.zogenix.com.
CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]
Media: Rachel Lipsitz
Public Relations, INC Research/inVentivHealth
858-449-9575 | [email protected]
